Ikoma, Japan

Noriko Kawashima

USPTO Granted Patents = 1 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Noriko Kawashima - Innovator in Therapeutic Compounds

Noriko Kawashima is a prominent inventor based in Ikoma, Japan. She has made significant contributions to the field of medicinal chemistry, particularly in the development of therapeutic agents. Her work focuses on compounds that have the potential to treat diseases associated with interleukin-6.

Latest Patents

Noriko Kawashima holds a patent for a pyrrole derivative that features substituents such as a ureido group, an aminocarbonyl group, and a bicyclic group. This compound, represented by a specific formula, exhibits inhibitory activity on the production of interleukin-6. As a result, it is considered useful as a therapeutic agent for ocular inflammatory diseases and other related conditions. The patent highlights the versatility of the compound, with various substituents that can be incorporated into its structure.

Career Highlights

Kawashima is currently employed at Santen Pharmaceutical Co., Ltd., where she continues to advance her research in therapeutic compounds. Her innovative work has led to the development of valuable medicinal products that address significant health issues. With a focus on interleukin-6, her research is at the forefront of therapeutic advancements.

Collaborations

Noriko Kawashima has collaborated with notable colleagues, including Kenji Kawashima and Hiroshi Enomoto. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic agents.

Conclusion

In summary, Noriko Kawashima is a distinguished inventor whose work in developing therapeutic compounds has the potential to make a significant impact in the medical field. Her innovative contributions continue to pave the way for advancements in treating diseases associated with interleukin-6.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…